NPSR1; TSHR; CXCR1; NMUR2; | |
ADRA2C; ADRA2A; DRD4; | |
ALPL; RECQL; PLA2G1B; TDP1; BLM; ALPI; CTDSP1; P4HB; PKM; PIK3CA; PIK3CB; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; NQO2; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; TNKS; TNKS2; PYGL; UGT1A1; APEX1; POLB; | |
PTPN1; CDC25B; | |
ACHE; GAA; BCHE; | |
CFTR; | |
BCL2; | |
FLT3; AKT1; MET; PRKCQ; CAMK2B; MAP4K4; MARK4; TBK1; FLT1; JAK2; CDK8; MAP3K10; LRRK2; CSNK2A1; DAPK1; SYK; JAK3; NEK2; AXL; STK3; NEK6; PKN1; ROCK2; TAOK1; GSK3A; SRC; IGF1R; PTK2; AURKB; DYRK1A; ROCK1; GSK3B; CAMK2A; CAMK1D; RPS6KA3; CAMKK2; PRKACA; KDR; GRK5; SGK2; CDK1; MAPK1; CSNK1A1; SIK2; PIM1; NUAK1; ALK; MAPK10; HCK; MARK3; ACVR1; ROS1; RET; TYRO3; IKBKE; DYRK1B; FGFR1; PDGFRA; CDK6; CLK2; BTK; LTK; PRKX; MELK; TNK2; | |
CA12; CA5A; CA3; CA14; CA5B; CA1; CA13; CA7; CA4; CA6; CA2; CA9; | |
AR; | |
ESRRA; | |
ESR2; ESR1; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; PTGS2; TYR; XDH; | |
MMP13; MMP3; MMP2; MMP9; MMP1; | |
ELANE; | |
BACE1; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
ABCC1; ABCG2; | |
SLC6A2; | |
LMNA; MCL1; MAPT; HTT; GMNN; THPO; RAB9A; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | UGT1A1 | UDP-glucuronosyltransferase 1-1 | P22309 | CHEMBL1287617 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
Protein Kinase | GSK3A | Glycogen synthase kinase-3 alpha | P49840 | CHEMBL2850 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | ROCK1 | Rho-associated protein kinase 1 | Q13464 | CHEMBL3231 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CAMK2A | CaM kinase II alpha | Q9UQM7 | CHEMBL4147 |
Protein Kinase | CAMK1D | CaM kinase I delta | Q8IU85 | CHEMBL5073 |
Protein Kinase | RPS6KA3 | Ribosomal protein S6 kinase alpha 3 | P51812 | CHEMBL2345 |
Protein Kinase | CAMKK2 | CaM-kinase kinase beta | Q96RR4 | CHEMBL5284 |
Protein Kinase | PRKACA | cAMP-dependent protein kinase alpha-catalytic subunit | P17612 | CHEMBL4101 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | GRK5 | G protein-coupled receptor kinase 5 | P34947 | CHEMBL5678 |
Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
Protein Kinase | SIK2 | Serine/threonine-protein kinase SIK2 | Q9H0K1 | CHEMBL5699 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
Protein Kinase | HCK | Tyrosine-protein kinase HCK | P08631 | CHEMBL3234 |
Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
Protein Kinase | ACVR1 | Activin receptor type-1 | Q04771 | CHEMBL5903 |
Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
Protein Kinase | IKBKE | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Q14164 | CHEMBL3529 |
Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
Protein Kinase | PDGFRA | Platelet-derived growth factor receptor alpha | P16234 | CHEMBL2007 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
Protein Kinase | BTK | Tyrosine-protein kinase BTK | Q06187 | CHEMBL5251 |
Protein Kinase | LTK | Leukocyte tyrosine kinase receptor | P29376 | CHEMBL5627 |
Protein Kinase | PRKX | Serine/threonine-protein kinase PRKX | P51817 | CHEMBL5818 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
Protein Kinase | MARK4 | MAP/microtubule affinity-regulating kinase 4 | Q96L34 | CHEMBL5754 |
Protein Kinase | TBK1 | Serine/threonine-protein kinase TBK1 | Q9UHD2 | CHEMBL5408 |
Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Q02779 | CHEMBL2873 |
Protein Kinase | LRRK2 | Leucine-rich repeat serine/threonine-protein kinase 2 | Q5S007 | CHEMBL1075104 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | TNK2 | Tyrosine kinase non-receptor protein 2 | Q07912 | CHEMBL4599 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.886E-13 | 1.159E-10 | ADRA2A, AURKB, BCL2, CA2, CA7, CDK6, CFTR, HIF1A, HTT, KDR, LRRK2, MAP4K4, MAPK1, NEK2, NPC1, NPSR1, PIK3CB, PLA2G1B, PRKACA, PRKCQ, PTGS2, SRC, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 8.335E-12 | 9.864E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, JAK2, MPO, NOX4, PTGS1, PTGS2, SRC |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.993E-11 | 2.272E-09 | AURKB, CA2, CA7, CFTR, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, PIK3CB, PLA2G1B, PRKCQ, PTGS2, SYK, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 2.246E-11 | 2.535E-09 | BTK, DYRK1A, HCK, JAK2, JAK3, MELK, PTK2, SRC, SYK, TNK2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.313E-11 | 9.703E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.920E-10 | 1.935E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.516E-10 | 7.210E-08 | ALPI, AR, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, GLO1, L3MBTL1, MMP1, MMP13, MMP2, MMP3, MMP9, NQO2, PTPN1, TNKS, TP53 |
BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 2.103E-09 | 1.916E-07 | ACVR1, AKT1, ALOX15, AXL, CAMK1D, CXCR1, ELANE, HCK, JAK3, NFKB1, NOX4, PIK3CA, PIK3CB, POLB, PRKCQ, PTGS1, PTGS2, SYK, TBK1, UGT1A1 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.212E-09 | 4.450E-07 | AURKB, MAPK1, NEK2, PRKCQ, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.072E-09 | 5.085E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.169E-08 | 9.424E-07 | AXL, FGFR1, MET, NOX4, PDGFRA, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC, STK3, THPO |
CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 1.501E-08 | 1.189E-06 | ALOX15, BTK, HCK, JAK2, JAK3, PTK2, SRC, SYK, TNK2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.081E-08 | 1.612E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.219E-08 | 1.701E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.337E-08 | 1.773E-06 | IGF1R, JAK2, PIK3CA, PIK3CB, PIK3R1 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.956E-08 | 2.853E-06 | AHR, AXL, BCL2, CSNK2A1, DRD4, DYRK1A, ESR1, GSK3B, MAPK10, PDGFRA, ROCK2, SRC, TP53, TYRO3, USP2 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.977E-08 | 2.858E-06 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 4.062E-08 | 2.894E-06 | ABCG2, ACHE, ACVR1, ADRA2A, ADRA2C, AKT1, BCL2, BLM, CAMK2A, CAMK2B, FGFR1, FLT3, HPGD, LRRK2, MAP3K10, MAPT, MCL1, NFKB1, NQO2, PDGFRA, PTGS2, PYGL, TYR, UGT1A1, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.067E-08 | 2.894E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.982E-08 | 6.093E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.740E-07 | 1.121E-05 | AKT1, BCL2, HIF1A, LRRK2, MCL1, MMP9, PTGS2, PTPN1, SRC |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 2.081E-07 | 1.310E-05 | FLT1, FLT3, KDR, PDGFRA |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.131E-07 | 1.326E-05 | BCL2, MCL1, PIK3CA, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.131E-07 | 1.326E-05 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 3.496E-07 | 2.115E-05 | ACVR1, AKT1, AR, BCL2, DAPK1, HTT, LMNA, MCL1, SRC |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 4.996E-07 | 2.948E-05 | AURKB, MAPK1, NEK2, PRKCQ, TNKS, TNKS2 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.124E-07 | 4.053E-05 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BCL2, BLM, CAMK2A, CAMK2B, CDC25B, CDK1, CDK6, CDK8, CLK2, CSNK2A1, CTDSP1, DYRK1A, ESR1, ESR2, ESRRA, GMNN, GSK3B, HCK, HIF1A, HPGD, HTT, JAK2, L3MBTL1, LMNA, MAPK1, MAPK10, MCL1, NEK2, NEK6, NFKB1, NQO2, NUAK1, PIM1, PKN1, POLB, PRKACA, RECQL, RPS6KA3, SGK2, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 9.870E-07 | 5.554E-05 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1, UGT1A1 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.252E-06 | 6.921E-05 | ALPL, AXL, CYP1A1, CYP1A2, ELANE, HPGD, JAK2, MPO, NFKB1, PTGS2, RPS6KA3, SRC, UGT1A1 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.470E-06 | 8.061E-05 | ACVR1, ADRA2C, AKT1, APP, AR, AXL, BCL2, BTK, CA2, CAMK1D, CAMK2B, FGFR1, HIF1A, JAK2, KDR, LTK, MAPT, NFKB1, PTGS2, RET, RPS6KA3, STK3, SYK, THPO |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.969E-38 | 3.299E-35 | ABCC1, ABCG2, ACVR1, AKT1, ALK, AURKB, AXL, BLM, BTK, CAMK1D, CAMK2A, CAMK2B, CAMKK2, CDK1, CDK6, CDK8, CFTR, CLK2, CSNK1A1, CSNK2A1, DAPK1, DYRK1A, DYRK1B, FGFR1, FLT1, FLT3, GRK5, GSK3A, GSK3B, HCK, IGF1R, IKBKE, JAK2, JAK3, KDR, LRRK2, LTK, MAP3K10, MAP4K4, MAPK1, MAPK10, MARK3, MARK4, MELK, MET, NEK2, NEK6, NUAK1, PDGFRA, PIK3CA, PIK3CB, PIM1, PKM, PKN1, PRKACA, PRKCQ, PRKX, PTK2, PYGL, RECQL, RET, ROCK1, ROCK2, ROS1, RPS6KA3, SGK2, SIK2, SRC, STK3, SYK, TAOK1, TBK1, TNK2, TP53, TYRO3 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.966E-06 | 1.047E-04 | FGFR1, FLT1, FLT3, JAK2, KDR, PDGFRA, PTK2 |
BP | GO:0051179; localization | GO:0033160; positive regulation of protein import into nucleus, translocation | 2.842E-06 | 1.443E-04 | CDK1, JAK2, LRRK2, MAPK1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.842E-06 | 1.443E-04 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.183E-06 | 2.033E-04 | AKT1, BCL2, HIF1A, LMNA, P4HB, PTGS2, SRC, TP53 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 4.397E-06 | 2.128E-04 | AKT1, BCL2, MAPT, PTPN1, TP53 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 5.275E-06 | 2.502E-04 | AXL, IGF1R, JAK2, PIK3R1, TYRO3 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 6.284E-06 | 2.956E-04 | FLT1, FLT3, PDGFRA, PTK2, SRC |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.848E-06 | 3.146E-04 | CYP1A1, CYP2C8, CYP3A4 |
CC | GO:0044464; cell part | GO:0042995; cell projection | 7.597E-06 | 3.453E-04 | ADRA2C, AKR1B1, APP, BACE1, CA2, CAMK2A, CAMK2B, CAMKK2, CDK6, CSNK1A1, GSK3A, HCK, HIF1A, HTT, LRRK2, MAPK1, MAPK10, MAPT, MARK4, PIK3CA, PKM, PRKACA, PTGS2, PTK2, RET, ROCK1, SLC6A2, SMN1, SMN2, SRC |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 7.676E-06 | 3.475E-04 | FLT1, FLT3, KDR, PDGFRA |
BP | GO:0050896; response to stimulus | GO:0060397; JAK-STAT cascade involved in growth hormone signaling pathway | 7.676E-06 | 3.475E-04 | JAK2, JAK3, MAPK1, PTPN1 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.754E-06 | 3.914E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.320E-05 | 5.771E-04 | AURKB, CDK1, JAK2, PKN1 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.361E-05 | 5.937E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.577E-05 | 6.759E-04 | AKT1, JAK2, MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.691E-05 | 7.133E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.777E-05 | 7.471E-04 | BCL2, CA2, CA7, HTT, KDR, LRRK2, NPSR1, PLA2G1B, PRKACA, SRC |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 2.090E-05 | 8.618E-04 | AKT1, PRKCQ, PTK2, ROCK1, TAOK1 |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 2.169E-05 | 8.859E-04 | HCK, MAPK1, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.366E-05 | 9.574E-04 | BCHE, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 2.535E-05 | 1.020E-03 | ADRA2A, ADRA2C, FLT3, JAK2, PTPN1, SRC, SYK, TNK2, TP53 |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 2.667E-05 | 1.066E-03 | FGFR1, MET, PDGFRA, PIK3CA, PIK3CB, PIK3R1 |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 2.767E-05 | 1.096E-03 | ALOX15, APP, AXL, CAMK1D, HCK, PIK3CB, PTPN1, SRC, SYK, TNK2 |
BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 2.938E-05 | 1.155E-03 | AKT1, APP, BCL2, PIK3CA, PTGS2, RET, TBK1 |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 3.166E-05 | 1.229E-03 | BCL2, IKBKE, MCL1, PIK3R1, POLB, TP53 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 3.553E-05 | 1.365E-03 | AKT1, APEX1, BCL2, CA5A, CA5B, CAMK2A, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3A, GSK3B, HSD17B10, LRRK2, MAOA, MAPK1, MAPK10, MCL1, MMP2, MPO, NFKB1, NOX4, PKM, PRKACA, SRC, TP53 |
CC | GO:0044464; cell part | GO:0005764; lysosome | 3.596E-05 | 1.374E-03 | AKR1B1, AKR1B10, BTK, GAA, HCK, LRRK2, MPO, NPC1, RAB9A, SRC, TYR |
BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 3.698E-05 | 1.403E-03 | ALK, APP, AR, BTK, CAMK2A, NFKB1, PLA2G1B, PRKCQ |
MF | GO:0005488; binding | GO:0002039; p53 binding | 3.737E-05 | 1.414E-03 | BLM, GSK3B, HIF1A, HTT, NUAK1, TP53 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.760E-05 | 1.414E-03 | ADRA2A, ADRA2C, DRD4 |
CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 3.760E-05 | 1.414E-03 | ALOX5, APP, BCHE |
BP | GO:0065007; biological regulation | GO:0006874; cellular calcium ion homeostasis | 3.845E-05 | 1.443E-03 | APP, BCL2, DRD4, ELANE, ESR1, HTT, JAK2, NMUR2, NPSR1, PDGFRA, PIK3CB, PLA2G1B, PRKACA |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 3.918E-05 | 1.466E-03 | HPGD, JAK2, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0060326; cell chemotaxis | 3.943E-05 | 1.471E-03 | ABCC1, CXCR1, FLT1, PDGFRA, PIK3CA, PIK3CB, PLA2G1B, PRKCQ, SYK |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 4.001E-05 | 1.484E-03 | ADRA2A, ADRA2C, AHR, AXL, BCL2, HIF1A, MCL1, NFKB1, P4HB, PIK3R1, TP53, TTR, TYR, TYRO3, UGT1A1 |
BP | GO:0051704; multi-organism process | GO:0044419; interspecies interaction between organisms | 4.439E-05 | 1.627E-03 | AXL, CDK1, DYRK1A, ELANE, HCK, KDR, MAPK1, MET, MMP1, NPC1, PDGFRA, PIK3R1, RAB9A, ROCK2, SRC, SYK, TBK1, TP53, TYRO3 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 4.565E-05 | 1.671E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 4.747E-05 | 1.728E-03 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:2001239; regulation of extrinsic apoptotic signaling pathway in absence of ligand | 5.388E-05 | 1.933E-03 | AKT1, BCL2, FGFR1, MCL1, RET |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 5.603E-05 | 1.990E-03 | BLM, RECQL, TP53 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.603E-05 | 1.990E-03 | KDR, SYK, TYRO3 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.963E-05 | 2.101E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM, UGT1A1 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 7.417E-05 | 2.547E-03 | ELANE, MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.883E-05 | 2.637E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 7.883E-05 | 2.637E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 7.883E-05 | 2.637E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.883E-05 | 2.637E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 7.883E-05 | 2.637E-03 | ACHE, BCHE |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 7.883E-05 | 2.637E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 7.952E-05 | 2.642E-03 | CA2, CA7, CFTR |
BP | GO:0008152; metabolic process | GO:0051172; negative regulation of nitrogen compound metabolic process | 8.308E-05 | 2.749E-03 | ADRA2A, AHR, AKT1, APEX1, APP, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, DRD4, DYRK1A, ELANE, ESR1, ESR2, ESRRA, FGFR1, GMNN, GSK3A, IGF1R, JAK3, L3MBTL1, LRRK2, MAP3K10, MMP9, NFKB1, PKN1, PTGS2, PTPN1, ROCK1, ROCK2, RPS6KA3, SRC, STAT6, TNKS, TNKS2, TP53, USP2, XDH |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 9.095E-05 | 2.961E-03 | ADRA2A, AKT1, HIF1A, NOX4, PIK3CA, PIK3R1, PRKACA, PYGL |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.052E-04 | 3.358E-03 | AURKB, CDK1, JAK2, PKN1 |
BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.057E-04 | 3.365E-03 | AURKB, CDK1, HTT, LMNA, MAPT, MARK3, MARK4, NEK2, NEK6, PTK2, TNKS |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.086E-04 | 3.427E-03 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.086E-04 | 3.427E-03 | GSK3B, HTT, MAPT |
CC | GO:0032991; macromolecular complex | GO:0030877; beta-catenin destruction complex | 1.086E-04 | 3.427E-03 | CSNK1A1, GSK3A, GSK3B |
BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 1.174E-04 | 3.656E-03 | KDR, PTK2, ROCK1, ROCK2, SRC |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.192E-04 | 3.691E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.282E-04 | 3.931E-03 | CDK1, FGFR1, IGF1R, PDGFRA, PLA2G1B |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 1.439E-04 | 4.358E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0050896; response to stimulus | GO:0038166; angiotensin-activated signaling pathway | 1.439E-04 | 4.358E-03 | CA2, CAMK2A, SRC |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.517E-04 | 4.583E-03 | ABCG2, ACVR1, ADRA2A, AHR, APP, FGFR1, FLT1, IGF1R, RET, SYK, TSHR |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.583E-04 | 4.742E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.793E-04 | 5.238E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.836E-04 | 5.345E-03 | AKT1, AURKB, BLM, CSNK2A1, DYRK1A, L3MBTL1, NUAK1, TP53 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.858E-04 | 5.381E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:2001028; positive regulation of endothelial cell chemotaxis | 1.858E-04 | 5.381E-03 | FGFR1, KDR, MET |
MF | GO:0003824; catalytic activity | GO:0050321; tau-protein kinase activity | 1.858E-04 | 5.381E-03 | GSK3A, GSK3B, MARK4 |
BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 2.031E-04 | 5.803E-03 | ESR1, FGFR1, FLT1, PDGFRA |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 2.061E-04 | 5.874E-03 | ACHE, ALOX15, BCL2, CDK1, CYP1A1, JAK2, PDGFRA, TP53 |
BP | GO:0009987; cellular process | GO:0001558; regulation of cell growth | 2.115E-04 | 6.005E-03 | AKT1, ALOX12, BCL2, CSNK2A1, ESR2, GSK3A, MAPT, PRKCQ, ROS1, RPS6KA3, SGK2, TP53 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 2.255E-04 | 6.360E-03 | ACHE, AKR1B1, APEX1, APP, BTK, CA4, HTT, NOX4, NPC1, PRKACA, ROS1, SRC, TNK2, TNKS2, TYR, USP2 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 2.285E-04 | 6.421E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0050896; response to stimulus | GO:0071870; cellular response to catecholamine stimulus | 2.285E-04 | 6.421E-03 | APP, LRRK2, MAPK1, PRKACA |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 2.350E-04 | 6.464E-03 | CYP19A1, ESR1, SRC |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.351E-04 | 6.464E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.351E-04 | 6.464E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.351E-04 | 6.464E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.351E-04 | 6.464E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.351E-04 | 6.464E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.351E-04 | 6.464E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.383E-04 | 6.534E-03 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 2.403E-04 | 6.574E-03 | BCL2, ELANE, ESR2, GSK3A, HIF1A, MPO, PTK2, STK3, TP53 |
MF | GO:0005488; binding | GO:0001784; phosphotyrosine residue binding | 2.562E-04 | 6.975E-03 | HCK, MAPK1, PIK3R1, SYK |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 2.583E-04 | 7.021E-03 | FGFR1, MET, PDGFRA, PIK3CA, PIK3CB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.833E-04 | 7.654E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 2.918E-04 | 7.825E-03 | LRRK2, MAPK1, MAPK10 |
BP | GO:0009987; cellular process | GO:0034976; response to endoplasmic reticulum stress | 2.992E-04 | 8.015E-03 | ALOX15, BCL2, GSK3A, GSK3B, LMNA, P4HB, PIK3R1, PTPN1, TP53 |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 3.103E-04 | 8.291E-03 | APEX1, APP, CDC25B, CDK1, CYP1A1, FGFR1, USP2 |
BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 3.188E-04 | 8.414E-03 | ADRA2A, ADRA2C, AKT1, MMP9 |
BP | GO:0008152; metabolic process | GO:0033619; membrane protein proteolysis | 3.188E-04 | 8.414E-03 | BACE1, NFKB1, PRKCQ, RET |
MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 3.188E-04 | 8.414E-03 | AHR, ESR1, NEK6, TP53 |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.265E-04 | 8.598E-03 | AKR1B1, HIF1A, LRRK2, MAPK1, MAPT |
MF | Unclassified; | GO:0004872; receptor activity | 3.310E-04 | 8.706E-03 | ACVR1, ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, ESRRA, FGFR1, FLT1, FLT3, HPGD, IGF1R, KDR, LTK, MET, NMUR2, NPC1, NPSR1, PDGFRA, RET, ROS1, TSHR, TYRO3 |
BP | GO:0032501; multicellular organismal process | GO:0048265; response to pain | 3.568E-04 | 9.227E-03 | NMUR2, RET, SLC6A2 |
MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 3.568E-04 | 9.227E-03 | CDK1, CDK8, MAPK1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.487E-23 | 2.911E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.697E-21 | 2.054E-18 | ACVR1, AKT1, BCL2, CAMK1D, CAMK2A, CAMK2B, CAMKK2, CDK1, CSNK2A1, DYRK1A, GSK3A, GSK3B, LRRK2, MAP3K10, MAPK1, PKN1, TBK1, TNKS |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.711E-17 | 1.173E-14 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.001E-14 | 1.677E-12 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.668E-13 | 3.748E-11 | BTK, HCK, IGF1R, JAK2, JAK3, KDR, PTK2, ROS1, SRC, SYK, TNK2 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 5.575E-13 | 7.587E-11 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, AURKB, BCL2, BLM, BTK, CA1, CA13, CA2, CA3, CA7, CAMK2A, CAMK2B, CAMKK2, CDC25B, CDK1, CDK6, CFTR, CSNK1A1, CSNK2A1, FGFR1, FLT3, GFER, GLO1, GMNN, GRK5, GSK3A, GSK3B, HCK, HIF1A, HPGD, HSD17B1, HTT, IKBKE, JAK2, JAK3, LMNA, LRRK2, MAPK1, MAPK10, MAPT, MARK3, MARK4, MCL1, NEK2, NEK6, NFKB1, NQO2, PIK3CA, PIK3CB, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PRKACA, PRKCQ, PTK2, PTPN1, PYGL, RAB9A, RET, ROCK1, ROCK2, RPS6KA3, SGK2, SMN1, SMN2, SRC, STAT6, STK3, SYK, TAOK1, TBK1, TNKS, TNKS2, TP53, TYR, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.856E-18 | 8.170E-16 | RET; GSK3B; ROCK1; ROCK2; FLT3; PIK3CB; PIK3R1; PTGS2; HIF1A; IGF1R; AKT1; MAPK1; PRKACA; PDGFRA; MMP1; DAPK1; MMP2; MMP9; NFKB1; PTK2; MAPK10; AR; CDK6; PIK3CA; BCL2; MET; TP53; FGFR1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.613E-22 | 1.375E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.113E-17 | 4.238E-15 | CAMK2B; ROCK1; ROCK2; SRC; MMP2; CAMK2A; PIK3R1; PIK3CB; HIF1A; ESR1; MMP9; PTK2; IGF1R; PIK3CA; KDR; AKT1; MAPK1; PRKACA; TP53; MET; FGFR1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.215E-14 | 9.216E-13 | PDGFRA; GSK3B; FLT1; SYK; PIK3R1; PIK3CB; PTK2; NFKB1; IGF1R; CDK6; PIK3CA; KDR; BCL2; AKT1; MAPK1; PKN1; JAK2; TP53; SGK2; JAK3; MET; FGFR1; MCL1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.509E-14 | 7.847E-13 | RET; PDGFRA; FLT3; PIK3CB; PIK3R1; HIF1A; PKM; PIK3CA; AKT1; MAPK1; TP53; MET; FGFR1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.027E-14 | 1.396E-12 | GSK3B; GSK3A; ROCK1; ROCK2; SRC; PIK3R1; PIK3CB; NFKB1; PTK2; HCK; PIK3CA; GRK5; CXCR1; AKT1; MAPK1; PRKACA; JAK2; JAK3 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.103E-13 | 2.050E-11 | PDGFRA; GSK3B; PIK3CB; PIK3R1; NFKB1; IGF1R; AR; PIK3CA; BCL2; AKT1; MAPK1; TP53; FGFR1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.092E-12 | 2.523E-11 | MAPK10; GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; JAK2; ESR1; NFKB1; ESR2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 7.883E-13 | 2.050E-11 | GSK3B; CSNK2A1; PIK3R1; PIK3CB; NFKB1; TBK1; CDK6; PIK3CA; AKT1; RAB9A; PRKCQ; JAK2; TP53; JAK3; IKBKE |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.913E-12 | 3.979E-11 | PDGFRA; GSK3B; FLT1; ROCK1; ROCK2; SRC; PIK3R1; PIK3CB; PTK2; IGF1R; MAPK10; PIK3CA; KDR; BCL2; AKT1; MAPK1; MET |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.246E-12 | 4.247E-11 | SRC; PIK3R1; PIK3CB; MMP9; NFKB1; MAPK10; TBK1; CDK6; PIK3CA; BCL2; AKT1; MAPK1; STAT6; TP53; IKBKE |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.260E-12 | 1.432E-10 | CAMK2B; PDGFRA; CDK6; PIK3CA; CAMK2A; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; IGF1R |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.260E-11 | 3.616E-10 | PDGFRA; CDK6; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; MET; FGFR1; IGF1R |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.516E-11 | 5.224E-10 | CAMK2B; GSK3B; CAMK2A; PIK3R1; PIK3CB; NFKB1; MAPK10; RPS6KA3; PIK3CA; BCL2; AKT1; MAPK1; TP53 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.276E-10 | 1.658E-09 | PDGFRA; FLT1; PLA2G1B; PIK3R1; PIK3CB; NFKB1; IGF1R; MAPK10; TBK1; PIK3CA; KDR; AKT1; MAPK1; PRKACA; MET; FGFR1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.635E-11 | 1.197E-09 | CAMK2B; FLT1; PIK3CA; CAMK2A; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A; NFKB1; IGF1R |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.388E-10 | 2.614E-09 | GSK3B; SYK; CSNK2A1; PIK3R1; PIK3CB; NFKB1; MAPK10; TBK1; PIK3CA; BCL2; CDK1; AKT1; PRKACA; TP53; JAK3 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.196E-10 | 2.614E-09 | MAPK10; CAMK2B; GSK3B; PIK3CA; SRC; CAMK2A; AKT1; MAPK1; PIK3CB; PIK3R1; PTK2 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.333E-10 | 2.614E-09 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PRKACA; PTGS2; PTGS1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 6.366E-10 | 6.019E-09 | ROCK1; PIK3CA; SYK; ROCK2; SRC; BTK; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA; PTGS1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.123E-09 | 8.988E-09 | MAPK10; PIK3CA; MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; JAK2; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 8.098E-10 | 7.323E-09 | MAPK10; RPS6KA3; PIK3CA; CDK1; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA; CDC25B; IGF1R |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.120E-09 | 8.988E-09 | CAMK2B; CAMK1D; ROCK1; ROCK2; SRC; CAMK2A; PIK3R1; PIK3CB; PTGS2; CAMKK2; PIK3CA; MAPK1; PRKACA |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.248E-10 | 5.198E-09 | MAPK10; ABCC1; ROCK1; PIK3CA; ROCK2; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.043E-10 | 7.837E-09 | PIK3CA; SRC; MMP2; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA; ESR1; MMP9; ESR2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.966E-09 | 1.514E-08 | CAMK2B; ROCK1; ROCK2; CAMK2A; PIK3R1; PIK3CB; NFKB1; TSHR; MAPK10; PIK3CA; AKT1; MAPK1; PRKACA; CFTR |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.861E-10 | 4.015E-09 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; PRKACA; CYP19A1; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.890E-09 | 1.879E-08 | SYK; SRC; PIK3R1; PIK3CB; NFKB1; POLB; CDK6; PKM; PIK3CA; CDK1; MAPK1; PRKACA; TP53; JAK3 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.106E-09 | 1.958E-08 | CAMK2B; ACHE; PIK3CA; CAMK2A; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA; JAK2 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.556E-09 | 1.833E-08 | MAPK10; PTPN1; GSK3B; RPS6KA3; PIK3CA; AKT1; PRKCQ; PIK3R1; PIK3CB; PYGL; NFKB1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.464E-09 | 1.831E-08 | PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3CB; PIK3R1; PTGS2; PTK2 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.376E-09 | 3.490E-08 | PDGFRA; ABCC1; ROCK1; PTGS2; MMP9; NFKB1; CDC25B; CDK6; PIK3CA; PIM1; BCL2; CYP1B1; MAPK1; TP53; MET; MCL1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.862E-09 | 1.879E-08 | MAPK10; GSK3B; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.964E-09 | 3.352E-08 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA; TP53; ESR1; HIF1A |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.431E-09 | 2.099E-08 | CDK6; PIK3CA; BCL2; AKT1; PIK3CB; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.242E-08 | 6.568E-08 | MAPK10; CAMK2B; PIK3CA; SRC; CAMK2A; PRKCQ; ALOX12; PIK3R1; PIK3CB; PRKACA |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.862E-09 | 1.879E-08 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.104E-08 | 1.068E-07 | MAPK10; GSK3B; TBK1; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; IKBKE; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.070E-09 | 2.929E-08 | MAPK10; CDK6; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.590E-08 | 1.589E-07 | MAPK10; PIK3CA; LMNA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1; MCL1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 4.636E-08 | 1.928E-07 | PDGFRA; NFKB1; CDC25B; STK3; MAPK10; RPS6KA3; TAOK1; AKT1; MAPK1; MAPT; PRKACA; TP53; MAP4K4; FGFR1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.263E-08 | 6.568E-08 | GSK3B; PIK3CA; SYK; BTK; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.806E-08 | 1.649E-07 | MAPK10; PIK3CA; MMP3; AKT1; MAPK1; PIK3R1; PIK3CB; PTGS2; MMP9; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 4.159E-08 | 1.766E-07 | ACVR1; GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; JAK2; JAK3; FGFR1; IGF1R |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.297E-08 | 2.160E-07 | FLT1; HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; ELANE; NFKB1; PTK2; IGF1R |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.246E-07 | 4.628E-07 | PIK3CA; THPO; PIM1; BCL2; AKT1; STAT6; PIK3R1; PIK3CB; JAK2; JAK3; MCL1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.456E-08 | 2.926E-07 | MAPK10; PIK3CA; ALOX5; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; JAK2; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.997E-07 | 1.057E-06 | PDGFRA; FLT1; PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MET; FGFR1; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.822E-07 | 2.582E-06 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; FUT7; HSD17B1; ALOX5; HSD17B2; XDH; UGT1A1; GAA; TYR; CYP2C9; CYP2C8; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.186E-07 | 4.569E-07 | PIK3CA; AKT1; PIK3CB; PIK3R1; PRKACA; TP53; NFKB1; CAMKK2; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.540E-08 | 1.229E-07 | PIK3CA; AKT1; PIK3CB; PIK3R1; PTGS2; PRKACA; TSHR; PTGS1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.569E-08 | 1.589E-07 | CYP2C9; CYP2C8; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.503E-07 | 1.175E-06 | MAPK10; GSK3B; TBK1; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; JAK2; IKBKE; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.540E-08 | 1.229E-07 | ALK; CDK6; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.934E-08 | 1.387E-07 | PIK3CA; FLT3; PIM1; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.353E-07 | 1.162E-06 | MAPK10; TBK1; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; IKBKE; NFKB1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.491E-07 | 1.175E-06 | MAPK10; PTPN1; GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; PYGL; PRKACA |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.211E-07 | 4.580E-07 | MAPK10; PIK3CA; SYK; BTK; AKT1; MAPK1; PIK3CB; PIK3R1 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.767E-06 | 5.487E-06 | MAPK10; CAMK2B; GSK3B; GSK3A; MAOA; CAMK2A; AKT1; PRKACA; DRD4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.123E-07 | 7.749E-07 | CDK6; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.141E-06 | 6.453E-06 | MAPK10; PIK3CA; SYK; BTK; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.344E-06 | 9.591E-06 | MAPK10; CAMK2B; SYK; SRC; CAMK2A; BCL2; AKT1; MAPK1; JAK2; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.378E-08 | 1.562E-07 | UGT1A1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.916E-06 | 1.086E-05 | MAPK10; CAMK2B; GSK3B; CSNK2A1; ROCK2; CSNK1A1; CAMK2A; PRKACA; TP53 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.603E-06 | 7.735E-06 | MAPK10; PDGFRA; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 5.497E-06 | 1.504E-05 | CAMK2B; PIK3CA; CAMK2A; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; PRKACA |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.506E-05 | 3.867E-05 | POLB; PDGFRA; GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; PRKACA; TP53; JAK3; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.246E-06 | 9.510E-06 | GSK3B; PIK3CA; AKT1; MAPK1; PRKCQ; PIK3R1; PIK3CB; NFKB1 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.460E-05 | 3.795E-05 | ROCK1; PIK3CA; ROCK2; AKT1; MAPK1; PIK3R1; PIK3CB; ADRA2C; ADRA2A |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.691E-05 | 4.187E-05 | PDGFRA; ROCK1; PIK3CA; ROCK2; SRC; MAPK1; PIK3R1; PIK3CB; PTK2; FGFR1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.130E-05 | 3.014E-05 | CAMK2B; AR; RPS6KA3; CAMK2A; CDK1; MAPK1; PRKACA; IGF1R |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 8.326E-06 | 2.249E-05 | ROCK1; PIK3CA; ROCK2; MMP2; PIK3R1; PIK3CB; MMP9; PTK2 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.000E-05 | 4.810E-05 | MAPK10; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; SGK2; IGF1R |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.358E-05 | 3.575E-05 | MAPK10; CAMK2B; SRC; MMP2; CAMK2A; MAPK1; PRKACA |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.545E-05 | 8.102E-05 | PDGFRA; PIK3CA; SYK; CXCR1; AKT1; MAPK1; PIK3R1; PIK3CB |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.971E-05 | 1.112E-04 | MAPK10; GSK3B; GSK3A; PIK3CA; AKT1; PIK3R1; PIK3CB; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.043E-04 | 4.380E-04 | MAPK10; TBK1; CSNK2A1; CDK1; JAK2; TP53; IKBKE; NFKB1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 4.186E-04 | 8.293E-04 | RET; PDGFRA; FLT1; CXCR1; GRK5; SRC; KDR; MET; IGF1R |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.567E-05 | 3.926E-05 | HCK; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.129E-03 | 3.903E-03 | ACVR1; PDGFRA; FLT1; CXCR1; THPO; FLT3; KDR; MET |
hsa04530 | Tight junction_Homo sapiens_hsa04530 | 3.216E-02 | 4.883E-02 | CSNK2A1; SRC; AKT1; PRKCQ |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.564E-06 | 4.930E-06 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; MET; HIF1A |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.685E-05 | 6.346E-05 | CAMK2B; PKM; CAMK2A; AKT1; SIK2; PYGL; PRKACA |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 9.961E-05 | 2.158E-04 | PIK3CA; AKT1; PIK3R1; PIK3CB; CFTR; IGF1R; CAMKK2 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 8.101E-07 | 2.633E-06 | RPS6KA3; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; HIF1A |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.363E-03 | 5.978E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.245E-05 | 7.501E-05 | MAPK10; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.567E-05 | 3.926E-05 | SYK; CSNK2A1; BCL2; BTK; PRKCQ; PTGS2; NFKB1 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 6.270E-03 | 1.060E-02 | PIK3CA; SYK; MAPK1; PIK3R1; PIK3CB |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.973E-07 | 1.057E-06 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.409E-06 | 4.508E-06 | CYP2C9; CYP2C8; UGT1A1; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.389E-03 | 7.608E-03 | GSK3B; CDK6; CDK1; TP53; CDC25B |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.266E-04 | 4.761E-04 | CAMK2B; GSK3B; CAMK2A; MAPK1; PRKACA; TYR |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.121E-06 | 6.453E-06 | CYP2C9; CYP2C8; UGT1A1; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.266E-04 | 4.761E-04 | PIK3CA; PIK3R1; PIK3CB; PRKACA; NFKB1; PTK2 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 8.124E-04 | 1.536E-03 | GSK3B; ROCK1; ROCK2; MAPK1; MET; PTK2 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.412E-06 | 9.591E-06 | PTPN1; CSNK2A1; SRC; MAPK1; MET; FGFR1; IGF1R |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 6.031E-04 | 1.161E-03 | ROCK1; ROCK2; PLA2G1B; MAPK1; PRKCQ; PRKACA |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.130E-02 | 1.823E-02 | MAPK10; MAPK1; PRKACA; PTGS2 |
hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 9.169E-03 | 1.490E-02 | CAMK2B; CAMK2A; MAPK1; PRKACA |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.688E-02 | 4.141E-02 | MAPK10; MAPK1; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.096E-09 | 2.434E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.868E-05 | 2.158E-04 | MAPK10; ROCK1; ROCK2; MAPK1; PKN1; NFKB1 |
hsa04925 | Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | 5.255E-03 | 9.034E-03 | CAMK2B; CAMK1D; CAMK2A; PRKACA |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.777E-04 | 1.832E-03 | PDGFRA; SRC; CDK1; MAPK1; PRKACA |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.164E-02 | 3.360E-02 | CDK6; CDK1; TP53 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.705E-05 | 1.262E-04 | PIK3CA; SRC; PIK3CB; PIK3R1; MET; PTK2 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.625E-03 | 6.336E-03 | MAPK1; PTGS2; JAK2; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.410E-08 | 2.164E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 3.082E-05 | 7.204E-05 | MAPK10; AKT1; PRKCQ; JAK2; NFKB1; CAMKK2 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 4.428E-04 | 8.688E-04 | CAMK2B; CA2; CAMK2A; PRKACA; CFTR |
hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 3.115E-03 | 5.586E-03 | MAPK10; TBK1; IKBKE; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.918E-05 | 8.857E-05 | CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.775E-02 | 2.776E-02 | TBK1; IKBKE; NFKB1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.839E-05 | 4.500E-05 | PIK3CA; AKT1; PIK3CB; PIK3R1; PRKACA; IGF1R |
hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 2.656E-03 | 4.805E-03 | CAMK2B; MAOA; CAMK2A; PRKACA |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.654E-04 | 7.378E-04 | CA2; CYP3A4; PRKACA; CFTR; ABCG2 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 2.596E-04 | 5.400E-04 | CAMK2B; RPS6KA3; CAMK2A; MAPK1; PRKACA |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.986E-04 | 6.150E-04 | MAPK10; CXCR1; SRC; MET; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.302E-02 | 2.068E-02 | MAPK10; MAPK1; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.012E-05 | 4.810E-05 | MAPK10; ROCK1; ROCK2; SRC; MAPK1; NFKB1 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 1.241E-02 | 1.986E-02 | UGT1A1; GAA; PYGL |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 8.619E-03 | 1.423E-02 | MAOA; PRKACA; NFKB1 |
hsa04340 | Hedgehog signaling pathway_Homo sapiens_hsa04340 | 9.112E-03 | 1.490E-02 | GSK3B; CSNK1A1; PRKACA |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.372E-06 | 9.591E-06 | MAPK10; PKM; PIK3CA; MAPK1; PIK3CB; PIK3R1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 7.235E-03 | 1.204E-02 | UGT1A1; CYP3A4; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 6.392E-03 | 1.072E-02 | ABCC1; CFTR; ABCG2 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.261E-02 | 4.916E-02 | POLB; APEX1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 3.081E-02 | 4.712E-02 | AKR1B10; AKR1B1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 5.978E-04 | 1.161E-03 | PIK3CA; AKT1; PIK3CB; PIK3R1 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.435E-04 | 7.005E-04 | PIK3CA; MAPK1; PIK3CB; PIK3R1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.938E-03 | 3.598E-03 | RET; MAPK1; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.139E-03 | 3.903E-03 | AKR1B10; GAA; AKR1B1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.791E-04 | 7.583E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 3.623E-03 | 6.336E-03 | AKR1B10; UGT1A1; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.652E-02 | 2.604E-02 | CA2; CA4 |
hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 6.252E-03 | 1.060E-02 | ALPL; ALPI |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.229E-04 | 1.380E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; JAK2; FLT3; BCL2; ESR1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; BCL2; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PTGS2; PTGS2; MMP1; IKBKE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1; APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A; BCL2; FGFR1 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; RET; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | Colour dead tissues | NA | PTPN1 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; JAK2; ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; TP53 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; SYK; PIK3CA; FLT3; CA9; MMP2; PDGFRA; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; MELK; TP53; PIK3CB; ROS1; RET; FGFR1; KDR; KDR; KDR |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1 |
I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
NA: NA | Edema | NA | CA2 |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; JAK2; SRC; IGF1R; BCL2 |
J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
NA: NA | HIV infections | NA | AHR |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; GSK3A; AURKB; TP53; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; FLT1; MCL1; JAK2; CSNK2A1; SYK; PIK3CA; CA1; FLT3; FLT3; CA9; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; PTK2; TNK2; ROCK1; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; CDC25B; BCL2; BCL2; TP53; PIK3CB; RET; ESR1; ESR1; FGFR1; KDR; APP |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | FLT1; CA9; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1; PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; JAK2; FLT3; FLT3; CA9; NQO2; IGF1R; CYP19A1; CDK1; BCL2; ESR1; ESR1; KDR; KDR; KDR |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; BCL2 |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT1; FLT3; MMP2; PTGS2; KDR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; GSK3A |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CAMK2A; SLC6A2; CYP3A4 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; FLT1; CYP19A1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | ROCK1; HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ROCK1; ADRA2C; MMP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1 |
NA: NA | GIST | NA | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PDGFRA; SRC |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ROCK1; CDK1; ADRA2C; ADRA2A; SLC6A2; ESR1 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; GSK3A; ADRA2C |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; ROCK1 |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | PDGFRA; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ROCK1; ADRA2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ELANE; ELANE; ROCK1 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | PDGFRA |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; ELANE; ELANE; CFTR |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C; SLC6A2 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PRKCQ; MPO; PLA2G1B; ALOX5; MMP13; SYK; ELANE; PTGS1; PTGS2; ROCK1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; GSK3B |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA; FGFR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PDGFRA; PTGS2; IGF1R; IGF1R; AXL; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; SLC6A2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; ELANE; PTGS2; ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1; APP |
C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE; RET |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
C00-D49: Neoplasms | Acute promyelocytic leukemia | C92.4 | GSK3A |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; MARK3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE; MMP3 |
NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PDGFRA; KDR; KDR; KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
NA: NA | Myeloproliferative neoplasm | NA | JAK2 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | JAK2; FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; ELANE; ROCK2; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; CAMK2A; TYR; MMP1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
NA: NA | Joint and muscular pain | NA | PTGS2 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |